Gemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as first-line chemotherapy in patients with advanced pancreatic cancer: Comparative effectiveness study.

被引：0
|
作者：
Cho, Jangho
Lim, Jae Yun
Cho, Jae Yong
机构：
[1] Gangnam Severance Hosp, Dept Med Oncol, Seoul, South Korea
[2] Gangnam Severance Hosp, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15132
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study
    Francois, E.
    Bennouna, J.
    Chamorey, E.
    Etienne-Grimaldi, M. C.
    Renee, N.
    Senellart, H.
    Michel, C.
    Follana, P.
    Mari, V.
    Douillard, J. Y.
    Milano, G.
    CHEMOTHERAPY, 2012, 58 (05) : 371 - 380
  • [12] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
    Arlen, Aimee Ginsburg
    Cartwright, Thomas H.
    Wilfong, Lalan S.
    Hoverman, J. Russell
    Nelson, Greg C.
    Turnwald, Brian
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [13] Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine
    Cartwright, Thomas H.
    Arlen, Aimee Ginsburg
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [14] Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer.
    Fang, Weijia
    Zhao, Peng
    Zheng, Yi
    Jiang, Weiqin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [15] Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Kulke, Matthew H.
    Blaszkowsky, Lawrence S.
    Ryan, David P.
    Clark, Jeffrey W.
    Meyerhardt, Jeffrey A.
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kwak, Eunice L.
    Muzikansky, Alona
    Lawrence, Colleen
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4787 - 4792
  • [16] Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer
    Delfino, C
    Caccia, G
    Gonzáles, LR
    Mickiewicz, E
    Rodger, J
    Balbiani, L
    Morales, DF
    Comba, AZ
    Brosio, C
    ONCOLOGY, 2004, 66 (01) : 18 - 23
  • [17] Gemcitabine Plus S-1 as First-line Chemotherapy in Chinese Patients With Advanced Pancreatic Cancer: A Prospective Study
    Wu, W.
    Zheng, Y.
    Jiang, W.
    Liu, L.
    Tong, Z.
    Zhang, H.
    Fang, W.
    Zhao, P.
    PANCREAS, 2019, 48 (10) : 1548 - 1548
  • [18] Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Possinger, K
    Kaufmann, M
    Coleman, R
    Stuart, NSA
    Helsing, M
    Ohnmacht, U
    Arning, M
    ANTI-CANCER DRUGS, 1999, 10 (02) : 155 - 162
  • [19] First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapyvscombination chemotherapy
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (18) : 4022 - 4033
  • [20] The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma : The TARGET study.
    Watkins, D. J.
    Starling, N.
    Chau, I.
    Thomas, J.
    Webb, J.
    Oates, J. R.
    Brown, G.
    Thomas, K.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345